Literature DB >> 15162546

Expression of subtypes of somatostatin receptors in hepatic stellate cells.

Sheng-Han Song1, Xi-Sheng Leng, Tao Li, Zhi-Zhong Qin, Ji-Run Peng, Li Zhao, Yu-Hua Wei, Xin Yu.   

Abstract

AIM: To elucidate the mechanism by which somatostatin and its analogue exert the influence on liver fibrosis, and to investigate the mRNA expression of somatostatin receptors subtypes (SSTRs) and the distribution of somatostatin analogue octreotide in rat hepatic stellate cells (HSCs).
METHODS: HSCs were isolated from Sprague Dawley (SD) rats by in situ perfusion and density gradient centrifugation. After several passages, the mRNA expression of 5 subtypes of SSTRs were assessed by reverse transcription-polymerase chain reaction (RT-PCR). HSCs were planted on coverslip and co-cultured with octreotide tagged by FITC. Then the distribution of FITC fluorescence was observed under laser scanning confocal microscope (LSCM) in 12-24 h.
RESULTS: There were mRNA expression of SSTR2, SSTR3 and SSTR5 but not SSTR1 and SSTR4 in SD rat HSCs. The mRNA expression level of SSTR2 was significantly higher than that of other subtypes (P<0.01). FITC fluorescence of octreotide was clearly observed on the surface and in the cytoplasm, but not in the nuclei of HSCs under LSCM.
CONCLUSION: The effect exerted by somatostatin and its analogues on HSCs may mainly depend on the expression of SSTR2, SSTR3 and SSTR5. Octreotide can perfectly combine with HSCs, and thereby exerts its biological activity on regulating the characters of active HSCs. This provides a potential prevention and management against liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15162546      PMCID: PMC4572775          DOI: 10.3748/wjg.v10.i11.1663

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  14 in total

Review 1.  Cytokine receptors and signaling in hepatic stellate cells.

Authors:  M Pinzani; F Marra
Journal:  Semin Liver Dis       Date:  2001-08       Impact factor: 6.115

Review 2.  Hepatic stellate cells: a target for the treatment of liver fibrosis.

Authors:  J Wu; M A Zern
Journal:  J Gastroenterol       Date:  2000       Impact factor: 7.527

Review 3.  Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis.

Authors:  M Pinzani; P Gentilini
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

4.  Effect of transforming growth factor beta and bone morphogenetic proteins on rat hepatic stellate cell proliferation and trans-differentiation.

Authors:  Hong Shen; Guo-Jiang Huang; Yue-Wen Gong
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

Review 5.  The role of somatostatin in schistosomiasis: a basis for immunomodulation in host-parasite interactions?

Authors:  S Chatterjee; E Van Marck
Journal:  Trop Med Int Health       Date:  2001-08       Impact factor: 2.622

6.  Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway.

Authors:  Chun-Hui Wang; Cheng-Wei Tang; Chun-Lun Liu; Li-Ping Tang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

7.  Somatostatin suppresses endothelin-1-induced rat hepatic stellate cell contraction via somatostatin receptor subtype 1.

Authors:  H Reynaert; F Vaeyens; H Qin; K Hellemans; N Chatterjee; D Winand; E Quartier; F Schuit; D Urbain; U Kumar; Y C Patel; A Geerts
Journal:  Gastroenterology       Date:  2001-10       Impact factor: 22.682

8.  Antifibrotic and hemodynamic effects of the early and chronic administration of octreotide in two models of liver fibrosis in rats.

Authors:  J Fort; F Oberti; C Pilette; N Veal; Y Gallois; O Douay; M C Rousselet; J Rosenbaum; P Calès
Journal:  Hepatology       Date:  1998-12       Impact factor: 17.425

Review 9.  Perspectives of new potential therapeutic applications of somatostatin analogs.

Authors:  Marek Pawlikowski; Gabriela Melen-Mucha
Journal:  Neuro Endocrinol Lett       Date:  2003 Feb-Apr       Impact factor: 0.765

10.  Somatostatin analogues suppress the inflammatory reaction in vivo.

Authors:  K Karalis; G Mastorakos; G P Chrousos; G Tolis
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

View more
  5 in total

Review 1.  Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver.

Authors:  Scott L Friedman
Journal:  Physiol Rev       Date:  2008-01       Impact factor: 37.312

2.  Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial.

Authors:  D Dimitroulopoulos; D Xinopoulos; K Tsamakidis; A Zisimopoulos; E Andriotis; D Panagiotakos; A Fotopoulou; C Chrysohoou; A Bazinis; D Daskalopoulou; E Paraskevas
Journal:  World J Gastroenterol       Date:  2007-06-21       Impact factor: 5.742

3.  Hepatic somatostatin receptor 2 expression during premalignant stages of hepatocellular carcinoma.

Authors:  N M Abdel-Hamid; O M Mohafez; S Zakaria; K Thabet
Journal:  Tumour Biol       Date:  2013-10-26

4.  Somatostatin analogue, Octreotide, improves restraint stress-induced liver injury by ameliorating oxidative stress, inflammatory response, and activation of hepatic stellate cells.

Authors:  Neven Makram Aziz; Merhan Mamdouh Ragy; Sabreen Mahmoud Ahmed
Journal:  Cell Stress Chaperones       Date:  2018-08-14       Impact factor: 3.667

5.  The Somatostatin Receptor-4 Agonist J-2156 Alleviates Mechanical Hypersensitivity in a Rat Model of Breast Cancer Induced Bone Pain.

Authors:  Priyank A Shenoy; Andy Kuo; Nemat Khan; Louise Gorham; Janet R Nicholson; Laura Corradini; Irina Vetter; Maree T Smith
Journal:  Front Pharmacol       Date:  2018-05-15       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.